TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05862610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib plus chemotherapy
Description: Trilaciclib: 240mg/m2 IV d1,within 4h before chemotherapy epirubicin: 100mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles cyclophosphamide:600mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles albumin-bound paclitaxel:100mg/m2 IV d1,8,15,Q3W,4cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: epirubicin: 100mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles cyclophosphamide:600mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles albumin-bound paclitaxel:100mg/m2 IV d1,8,15,Q3W,4cycles
Study: NCT04767698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: 200 mg SC weekly for 36 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short-course Ocrelizumab
Description: 300 mg, two infusions two weeks apart and then 600 mg as a single infusion after six months (only one time) (total of two courses of treatment)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continued Ocrelizumab
Description: 300 mg, two infusions two weeks apart and then 600 mg as a single infusion every six months for a total of 36 months
Study: NCT05264012

Intervention type: PROCEDURE
Intervention: Neurosurgery
Description: Neurosurgery

Intervention type: PROCEDURE
Intervention: Neurosurgery
Description: Neurosurgery
Study: NCT05515900

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium
Description: Daily sodium supplementation of 2000 mg.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium
Description: Daily sodium supplementation of 2000 mg.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB
Description: Daily HMB supplementation of 3 g.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB
Description: Daily HMB supplementation of 3 g.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills that will be identical to sodium or HMB supplementations
Study: NCT06523868

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GRAIL Galleri
Description: A multi-cancer early detection (MCED) blood test.
Study: NCT05485389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simulation based learning
Description: An educational methodology that aims to improve participants' attitudes towards the elderly and their perception of individualized care.
Study: NCT06115993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHB-137 injection
Description: AHB-137 injection will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHB-137 injection
Description: AHB-137 injection will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHB-137 injection
Description: AHB-137 injection will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered subcutaneously.
Study: NCT06167954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EXPLORER
Description: 8 sessions of use of the device in the home and the community of the participants
Study: NCT05796063

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: gastric point of care ultrasound
Description: Patients will receive a gastric point of care ultrasound to evaluate for delayed gastric emptying. Gastric POCUS studies will be obtained using Kosmos, a handheld portable ultrasound that is FDA approved for clinical use. This product has already been validated for use, and this is not a novel application of the technology.
Study: NCT05698927

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block (bilaterally, via 20ml % 0.25 bupivacain) and Intrathecal Morphine (100 mcg)
Description: Comparison of the postoperative opioid consumptions between Erector Spinae Plane Block (bilaterally, via 20ml % 0.25 bupivacain) and Intrathecal Morphine (100 mcg)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block (bilaterally, via 20ml % 0.25 bupivacain) and Intrathecal Morphine (100 mcg)
Description: Comparison of the postoperative opioid consumptions between Erector Spinae Plane Block (bilaterally, via 20ml % 0.25 bupivacain) and Intrathecal Morphine (100 mcg)
Study: NCT06048094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F fluciclovine
Description: Participants will receive 5-mCi dose (± 20%) of 18F-fluciclovine intravenously as a bolus injection immediately prior to PET data acquisition. PET data will be collected in list mode up to 25 minutes post-injection. PET images will be reconstructed in two ways: as a standard static image of data acquired between 10 to 20 minutes post-injection, and as a dynamic series of four 5-minute frames between 5 to 25 minutes post-injection to allow for motion assessment and correction and time-dependent observations.
Study: NCT04240288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided antibiotic treatment
Description: Antibiotics will be administered based on the procalcitonin lab results.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care Antibiotic Treatment
Description: Antibiotics will be administered based on standard of care treatment. The treating physicians will determine the treatment course.
Study: NCT04979832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF, fosfomycin and metronidazole
Description: GM-CSF 50 micrograms Fosfomycin 400 milligrams Metronidazole 100 milligrams applied as a gel in the pouch
Study: NCT05512208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avutometinib (VS-6766) + defactinib
Description: Avutometinib (VS-6766): will be administered at 3.2 mg orally twice a week Defactinib: will be administered at 200 mg orally twice a day (BID).~Treatment will be for 3 weeks, followed by a 1-week rest period, in each 4-week (28 day) cycle.
Study: NCT05383729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: learning-curve-based training modality
Description: It is an individual duration of simulation training that is based on the previous performance of FOB on a simulator.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fixed-training-time training modality
Description: It is a training duration of 1 hour which is the dominant duration of simulator training in previous studies.\[1\]
Study: NCT05012852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VagiVitalAC
Description: In the Pilot part, the single intervention used is VagiVitalAC treatment for 30 days. In the randomized part, patients in the Interventional arm are treated with VagiVital AC for up to 90 days.
Study: NCT05519046

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Contractility Modulation (CCM)
Description: Cardiac Contractility Modulation (CCM) implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT
Description: Cardiac Resynchronization Therapy
Study: NCT06195852

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Safe Touches
Description: The in-person Safe Touches workshop is delivered in the classroom by 2 facilitators with live puppet skits, as designed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Safe Touches
Description: The modified Safe Touches workshop will be delivered by 1 facilitator in the classroom by utilizing prerecorded workshop skit videos.
Study: NCT04565288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Participants randomized to receive the study medication, atomoxetine (brand name: Straterra) for 6-weeks (40 mg/day for 3 days then 80 mg/day thereafter). A comparator group will receive placebo (sugar pills).
Study: NCT06339736

Intervention type: OTHER
Intervention: Questionnaires administered to all study participants
Description: Ten treatment sessions were performed, which initially involved muscular stretching and relaxation exercises and then strengthening and endurance exercises to achieve stabilization. An oral splint was applied to he upper dental arch.

Intervention type: OTHER
Intervention: Questionnaires administered to all study participants
Description: Ten treatment sessions were performed, which initially involved muscular stretching and relaxation exercises and then strengthening and endurance exercises to achieve stabilization. An oral splint was applied to he upper dental arch.
Study: NCT04565288

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo (sugar pill)
Study: NCT06330701

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic-assisted mini-PCNL
Description: This robotically enabled hybrid procedure called the MONARCH Mini-PCNL will allow the clinician to obtain retrograde and percutaneous access to participant's kidney under continuous visualization for therapeutic applications (i.e., stone removal).
Study: NCT06410209

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal Setting
Description: Set physical activity goals

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal Setting
Description: Set physical activity goals

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Participate in a one-on-one interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: View private social media peer support group content

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: View private social media peer support group content

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear a Fitbit physical activity tracker

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear a Fitbit physical activity tracker

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Device Usage and Evaluation
Description: Wear a Fitbit physical activity tracker

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear a research grade activity measuring device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reward
Description: Receive badges

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message-Based Navigation Intervention
Description: Receive text messages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message-Based Navigation Intervention
Description: Receive reminders
Study: NCT04933149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Infustion
Description: Intravenous infusion at 0.5 mg/kg/hr from induction to emergence from anesthesia during the subject's brachial plexus reconstruction surgery. In addition, subjects will receive postoperative ketamine infusion of 0.1-0.3 mg/kg/hr for 24 hours titrated to side effects while patients are admitted to the hospital following surgery.
Study: NCT04746599

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Fat Grafting
Description: The trochanteric area or the periumbilical abdominal region represents the donor sites. Following Coleman's technique and after the administration of modified Klein solution, a skin incision is performed in the selected area. Adipose tissue is harvested and after suture the area is managed with an elastic-compressive dressing, to be kept in place for 5 days to prevent hematoma formation. The adipose tissue is the centrifuged at 920 × g for 3 min in sterile conditions. Only the intermediate layer containing adipocytes and stromal vascular component will be then injected using a blunt cannula. The terminal branches of the patient's leg arteries are mapped to facilitate graft placement. Under local anesthesia multiple injections of the adipose tissue formulation are inoculated 1 cm above the end of the terminal branch of the peroneal, anterior, and posterior tibial arteries.
Study: NCT04275804

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Magnitude High Frequence Vibration Platform
Description: with low-magnitude high-frequency vibration (35Hz, 0.3g peak-to-peak displacement \<0.1mm)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Dressing
Description: Alternate Day Dressing
Study: NCT05688085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan High/Amlodipine FDC
Description: Irbesartan High/Amlodipine FDC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan High
Description: Co-administration of Irbesartan High and Amlodipine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Co-administration of Irbesartan High and Amlodipine
Study: NCT06115993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered subcutaneously.
Study: NCT04855903

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Covirtua Cognition software
Description: Cognitive training with Covirtua Cognition software
Study: NCT04998578

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of aesthetic techniques
Description: Comparison of aesthetic techniques for rejuvenation and glazing of the genital region

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of aesthetic techniques
Description: Comparison of aesthetic techniques for rejuvenation and glazing of the genital region

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of aesthetic techniques
Description: Comparison of aesthetic techniques for rejuvenation and glazing of the genital region

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of aesthetic techniques
Description: Comparison of aesthetic techniques for rejuvenation and glazing of the genital region
Study: NCT04936776

Intervention type: BEHAVIORAL
Intervention: Text messaging
Description: Text parents of children (age 0-2yrs) who are due and due soon for a vaccine across the entire NYU-Brooklyn FHC network to increase vaccination rates.

Intervention type: BEHAVIORAL
Intervention: Text messaging
Description: Text parents of children (age 0-2yrs) who are due and due soon for a vaccine across the entire NYU-Brooklyn FHC network to increase vaccination rates.
Study: NCT04816747

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous PRP
Description: Participants enrolled in this study will be managed with intradiscal and/or intra-articular injections of autologous PRP according to features of underlying pathology. Participants featuring FJS will be prior to PRP diagnostically and therapeutically injected with local anesthetic in order to verify FJS as the etiology of experienced pain. Injected PRP solution volume is designed to be 0.5-1 ml and 0.5 ml in cases of intradiscal and intra-articular injection, respectively. All participants are planned to receive a single dose of PRP, whilst a maximum of two compromised discs and four facet joints will be treated in each patient.
Study: NCT02199015

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lateral spinal cord surgical implant of electrodes
Description: The procedure is based on the classic approaches to posterior cervical region for herniated discs, actually not longer employed for that aim A unilateral hemilaminectomy will be performed at C3-C4 level, starting from 4th cervical spinous process.~A multicontact electrode will be placed on the lateral surface of the spinal cord that will be subcutaneusly connected to an implanted pulse generator (IPG).
Study: NCT05265819

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: X-BOX kinetic360
Description: 1) Exergaming The practice of exergaming was performed using the Xbox 360 Kinect console,The volunteers carried out 36 exergaming sessions, with progressive increase in the duration of the games according to their tolerance,and reached a maximum duration of 50 minutes per session, included the realization of the games and the rest between activities. The exergaming protocol was performed two to three times a week, for a total of 12 weeks.
Study: NCT04855903

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Covirtua Cognition software
Description: Cognitive training with Covirtua Cognition software

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Covirtua Cognition software
Description: Cognitive training with Covirtua Cognition software
Study: NCT05924958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eprolidone
Description: This study assessed the effect of eplerenone on circulating Treg cells in patients with chronic heart failure by detecting the level of aldosterone in venous blood and the activity of Treg cells and the level of inflammatory factors related to it after taking drugs.
Study: NCT06299293

Intervention type: OTHER
Intervention: Facial Emotion Recognition Test
Description: In this test, the ability to detect and recognize facial expressions of fear or anger will be investigated.

Intervention type: OTHER
Intervention: Facial Emotion Recognition Test
Description: In this test, the ability to detect and recognize facial expressions of fear or anger will be investigated.
Study: NCT06611839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib,venetoclax,azacytidine,cytarabine
Description: phase I:Induction therapy：Ivosidenib 、Venetoclax、Cytarabine 、DNR or IDA~Dose climbing stage: adopt the 3 + 3 design principle, and the dose 0 group is set as follows~dose level 0: Ivosidenib 500mg d1-28 Venetoclax 100mg d-2，200mg d-1，400mg d1-7 Cytarabine 100mg/m2/d, d1-7 DNR 60mg/m2/d，d1-3 or IDA 12mg/m2/d，d1-3~dose level -1:Ivosidenib 500mg d1-28 Venetoclax 100mg d-2，200mg d-1，400mg d1-7 Cytarabine 100mg/m2/d, d1-5 DNR 60mg/m2/d，d1-2 or IDA 12mg/m2/d，d1-2~dose level 1:Ivosidenib 500mg d1-28 Venetoclax 100mg d-3，200mg d-2，400mg d-1 800mg d1-7 Cytarabine 100mg/m2/d, d1-7 DNR 60mg/m2/d，d1-3 or IDA 12mg/m2/d，d1-3~Consolidation therapy intermediate-dose cytarabine regimen ： 3 courses~If IDH1 mutant residual disease was positive before consolidation chemotherapy, Ivosidenib was added;~Maintenance treatment:~Azacytidine、Venetoclax 、Ivosidenib： 6 courses~phase II: dose based on phase I results
Study: NCT06675968

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct Suture
Description: A capsular closure will be performed, closure of the gluteus medius with a direct tendon and absorbable suture. Addittionally, the iliotibial band, subcutaneous and skin suture closure will be performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transosseus Suture
Description: A capsular closure will be performed, transosseous suture with a non-absorbable suture. Addittionally, the iliotibial band, subcutaneous and skin suture closure will be performed.
Study: NCT06676722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBRT combined with Nimotuzumab followed by Tislelizumab
Description: BRT combined with 3 cycles of Nimotuzumab 400mg qw followed by maintain Tislelizumab for 2 years or until disease progression
Study: NCT06677008

Intervention type: DEVICE
Intervention: Disposable endoscopic linear cutter stapler
Description: Investigational devices of all the models of the staplers and its cartridge listed in Study Plan(Plan number: CAK-PMCF)
Study: NCT06676215

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IAA mix supplement
Description: The intervention is a daily IAA dose that provides x1.5 the estimated average requirement (EAR) for a healthy child. This IAA dose will be mixed to the complementary food and will be taken once daily for 4 weeks (28 days) by the child in the intervention group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complementary food comprised of rice and legumes
Description: Each study child will receive standard complementary food which he/she will take once daily for 4 weeks (28 days)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complementary food comprised of rice and legumes
Description: Each study child will receive standard complementary food which he/she will take once daily for 4 weeks (28 days)
Study: NCT06676852

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary palliative care
Description: Enrolled patient participants will receive Sentinel prior to and during their hospitalization for HCT. Prior to HCT, a transplant clinician (nurse practitioner - NP) will conduct a focused PC visit to build rapport, manage expectations regarding HCT, review anticipated symptoms, and discuss illness coping strategies. During the HCT hospitalization, HCT physicians and advanced practice providers will incorporate PC domains into their routine care of patients undergoing HCT.
Study: NCT06676631

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK 010 or NK042
Description: NK010 is an allogeneic non-genetically modified NK cell infusion. NKX010 will be administered at a dose of 2.5 × 109 NK cells, 5.0 × 109 NK cells and 7.5 × 109 NK cells by a dose-escalation design and administered IV. N042 is an allogeneic genetic modification of NK cell. NKX042 will be administered at a dose of 6 × 108 NKR positive NK cells, 1.2 × 109 NKR positive NK cells and 2.4 × 109 NKR positive NK cells by a dose-escalation design and administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: RTX dose of 1 g administered IV over 60 minutes at the first day of the treatment phase.
Study: NCT06676527

Intervention type: OTHER
Intervention: Follow-up study of the treated cohort
Description: For those patients who have reached the end point of the study, survival data during treatment with vorolanib is obtained for retrospective analysis. The patients who are still on treatment with vorolanib are followed up closely and survival data is obtained for prospective analysis. After summarizing the results of retrospective and prospective studies, relevant efficacy and safety conclusions will be drawn.
Study: NCT06677463

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Studying the effect of virtual reality glasses on women during pregnancy, for the first time, it is also used to facilitate the birth process